Evidence map›Paper›PMID 28576909›Full record

ArticleBMJ case reports2017

Abciximab-induced delayed profound thrombocytopaenia.

Manar Jbara, Sukhdeep Bhogal, Kailash Bajaj, Lovely Chhabra

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Manar JbaraDepartment of Internal Medicine, East Tennessee State University, Johnson City, Tennessee, USA.
Sukhdeep BhogalDepartment of Internal Medicine, East Tennessee State University, Johnson City, Tennessee, USA.
Kailash BajajEast Tennessee State University, Kingsport, Tennessee, USA.
Lovely ChhabraHartford Hospital, University of Connecticut School of Medicine, Hartford, Connecticut, USA.
East Tennessee State University · USEastman Chemical Company (United States) · USUniversity of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary intervention of left anterior descending artery and was eventually diagnosed with abciximab-induced delayed thrombocytopaenia. This case outlines the importance of close follow-up of these patients to prevent serious adverse events.

Indexed as

AbciximabAntibodies, MonoclonalCoronary Artery DiseaseFemaleGlucocorticoidsHumansImmunoglobulin Fab FragmentsImmunoglobulins, IntravenousInfusions, IntravenousPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrednisoneThrombocytopeniaTreatment OutcomeYoung AdultAbciximabAntibodies, MonoclonalGlucocorticoidsImmunoglobulin Fab FragmentsImmunoglobulins, IntravenousPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrednisoneCardiovascular systemSafetyUnwanted effects / adverse reactions

Identifiers

PMID28576909
PMCPMC5534833
OpenAlexW2620847595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.